| Date | Time | Source | Headline | Symbol | Company |
| 05/27/2022 | 2:01AM | UK Regulatory | MaxCyte, Inc. Notice of AGM | LSE:MXCT | Maxcyte Inc |
| 05/16/2022 | 2:00AM | UK Regulatory | MaxCyte, Inc. Inducement Grants | LSE:MXCT | Maxcyte Inc |
| 05/10/2022 | 7:01AM | Alliance News |  IN BRIEF: MaxCyte first-quarter loss narrows; raises annual guidance | LSE:MXCT | Maxcyte Inc |
| 05/10/2022 | 3:41AM | UK Regulatory | MaxCyte, Inc. Filing of Form 10-Q | LSE:MXCT | Maxcyte Inc |
| 05/10/2022 | 3:41AM | UK Regulatory | MaxCyte, Inc. MaxCyte Reports First Quarter Financial Results | LSE:MXCT | Maxcyte Inc |
| 05/09/2022 | 4:05PM | PR Newswire (US) | MaxCyte Reports First Quarter Financial Results | LSE:MXCT | Maxcyte Inc |
| 05/04/2022 | 2:02AM | RNS Non-Regulatory | MaxCyte, Inc. Upcoming Investor Conferences | LSE:MXCT | Maxcyte Inc |
| 04/29/2022 | 9:41AM | UK Regulatory | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 04/19/2022 | 2:01AM | UK Regulatory | MaxCyte, Inc. Inducement Grants Under Nasdaq Listing Rule 5635 | LSE:MXCT | Maxcyte Inc |
| 04/13/2022 | 1:47PM | Alliance News | TRADING UPDATES: BlueRock output rises; Watkin Jones profit to fall | LSE:MXCT | Maxcyte Inc |
| 04/13/2022 | 2:00AM | UK Regulatory | MaxCyte, Inc. Departure of CFO and Preliminary Q1 2022 Revenue | LSE:MXCT | Maxcyte Inc |
| 04/11/2022 | 2:01AM | UK Regulatory | MaxCyte, Inc. Holding(s) in Company | LSE:MXCT | Maxcyte Inc |
| 04/01/2022 | 2:02AM | UK Regulatory | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 03/28/2022 | 8:19AM | UK Regulatory | MaxCyte, Inc. Grant of Options and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
| 03/28/2022 | 2:01AM | UK Regulatory | MaxCyte, Inc. Grant of Options and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
| 03/23/2022 | 1:22PM | Alliance News | MaxCyte widens net loss in 2021 while annual revenue increases | LSE:MXCT | Maxcyte Inc |
| 03/23/2022 | 3:00AM | UK Regulatory | MaxCyte, Inc. Fourth Quarter and Full Year Financial Results | LSE:MXCT | Maxcyte Inc |
| 03/22/2022 | 4:05PM | PR Newswire (US) | MaxCyte Reports Fourth Quarter and Full Year Financial Results | LSE:MXCT | Maxcyte Inc |
| 03/10/2022 | 10:57AM | Alliance News | IN BRIEF: MaxCyte hires chief scientist from Stemson Therapeutics | LSE:MXCT | Maxcyte Inc |
| 03/10/2022 | 2:00AM | UK Regulatory | MaxCyte, Inc. MaxCyte, Names Cenk Sumen Chief Scientific Officer | LSE:MXCT | Maxcyte Inc |
| 03/08/2022 | 9:29AM | UK Regulatory | MaxCyte, Inc. Holding(s) in Company | LSE:MXCT | Maxcyte Inc |
| 03/03/2022 | 4:45AM | UK Regulatory | MaxCyte, Inc. Holding(s) in Company | LSE:MXCT | Maxcyte Inc |
| 03/01/2022 | 2:01AM | UK Regulatory | MaxCyte, Inc. Block Listing Return | LSE:MXCT | Maxcyte Inc |
| 02/24/2022 | 8:00AM | UK Regulatory | MaxCyte, Inc. Notice of Results | LSE:MXCT | Maxcyte Inc |
| 02/22/2022 | 10:56AM | UK Regulatory | MaxCyte, Inc. Holding(s) in Company | LSE:MXCT | Maxcyte Inc |
| 02/21/2022 | 2:00AM | UK Regulatory | MaxCyte, Inc. Consolidation of Trading Lines | LSE:MXCT | Maxcyte Inc |
| 02/14/2022 | 7:59AM | UK Regulatory | MaxCyte, Inc. Upcoming Investor Conferences | LSE:MXCT | Maxcyte Inc |
| 02/14/2022 | 2:00AM | UK Regulatory | MaxCyte, Inc. Inducement Grants Under Nasdaq Listing Rule | LSE:MXCT | Maxcyte Inc |
| 02/01/2022 | 7:00AM | Alliance News | MaxCyte signs strategic platform pact with Intima Bioscience | LSE:MXCT | Maxcyte Inc |
| 02/01/2022 | 1:59AM | UK Regulatory | MaxCyte, Inc. License with Intima Bioscience | LSE:MXCT | Maxcyte Inc |